Advertisement

Single-fraction versus hypofractionated stereotactic radiosurgery for medium-sized brain metastases of 2.5 to 3 cm

  • Haemin Chon
  • KyoungJun Yoon
  • Doheui Lee
  • Do Hoon Kwon
  • Young Hyun ChoEmail author
Clinical Study
  • 2 Downloads

Abstract

Purpose

Given recently suggested utility of hypofractionated stereotactic radiosurgery (SRS) in treating large brain metastases (BMs) > 3 cm, we sought to prospectively control tumor size variable to investigate the efficacy and safety of hypofractionated SRS for medium-sized BMs (2.5 to 3 cm) compared with single-fraction SRS.

Methods

Between 2011 and 2015, a total of 100 patients with newly diagnosed BMs (n = 105) of 2.5 to 3 cm had been treated with either single-fraction (n = 67; median dose 20 Gy) or hypofractionated SRS (n = 38; median cumulative dose 35 Gy in 5 daily fractions). No patients received any prior or upfront whole brain radiotherapy. In each patient, treatment outcome was measured by local tumor control (LTC), overall and progression-free survival (OS and PFS), and the occurrence of radiation necrosis (RN).

Results

With a median follow-up of 14 months, significant differences were observed between the single-fraction versus hypofractionated SRS groups in the incidence of RN (29.9% vs. 5.3%, P < 0.001) and LTC (1-year LTC rates 66.6% vs. 92.4%, P = 0.028). There were no differences in PFS (median 6 months vs. 6 months, P = 0.381) and OS (median 13 months vs. 18 months, P = 0.239). Treatment-related adverse events ( ≥ grade 2 toxicity by CTCAE ver. 4.0) occurred more frequently in single-fraction group, although the difference did not reach statistical significance (56.3% vs. 36.1%, P = 0.084).

Conclusions

Our results suggest a better safety and efficacy profile of hypofractionated SRS for medium-sized BMs compared with single-fraction SRS. Further prospective studies are needed to confirm these results.

Keywords

Stereotactic radiosurgery Hypofractionation Brain metastases Radiation necrosis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

11060_2019_3265_MOESM1_ESM.docx (23 kb)
Supplementary file1 (DOCX 23 kb)

References

  1. 1.
    Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:45–68.  https://doi.org/10.1007/s11060-009-0073-4 CrossRefGoogle Scholar
  2. 2.
    Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298CrossRefGoogle Scholar
  3. 3.
    Giubilei C, Ingrosso G, D'Andrea M, Benassi M, Santoni R (2009) Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases. J Neurooncol 91:207–212.  https://doi.org/10.1007/s11060-008-9700-8 CrossRefGoogle Scholar
  4. 4.
    Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77:996–1001.  https://doi.org/10.1016/j.ijrobp.2009.06.006 CrossRefGoogle Scholar
  5. 5.
    Prabhu RS, Press RH, Patel KR, Boselli DM, Symanowski JT, Lankford SP, McCammon RJ, Moeller BJ, Heinzerling JH, Fasola CE, Asher AL, Sumrall AL, Buchwald ZS, Curran WJ Jr, Shu HG, Crocker I, Burri SH (2017) Single-fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS for large brain metastases: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 99:459–467.  https://doi.org/10.1016/j.ijrobp.2017.04.006 CrossRefGoogle Scholar
  6. 6.
    Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, Osti M, Enrici RM, Esposito V (2016) Single-fraction versus multifraction (3 × 9 Gy) stereotactic radiosurgery for large (%3e2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys 95:1142–1148.  https://doi.org/10.1016/j.ijrobp.2016.03.013 CrossRefGoogle Scholar
  7. 7.
    Han JH, Kim DG, Chung HT, Paek SH, Park CK, Jung HW (2012) Radiosurgery for large brain metastases. Int J Radiat Oncol Biol Phys 83:113–120.  https://doi.org/10.1016/j.ijrobp.2011.06.1965 CrossRefGoogle Scholar
  8. 8.
    Feuvret L, Vinchon S, Martin V, Lamproglou I, Halley A, Calugaru V, Chea M, Valery CA, Simon JM, Mazeron JJ (2014) Stereotactic radiotherapy for large solitary brain metastases. Cancer Radiother 18:97–106.  https://doi.org/10.1016/j.canrad.2013.12.003 CrossRefGoogle Scholar
  9. 9.
    Zimmerman AL, Murphy ES, Suh JH, Vogelbaum MA, Barnett GH, Angelov L, Ahluwalia M, Reddy CA, Chao ST (2016) Treatment of large brain metastases with stereotactic radiosurgery. Technol Cancer Res Treat 15:186–195.  https://doi.org/10.1177/1533034614568097 CrossRefGoogle Scholar
  10. 10.
    Kim JW, Park HR, Lee JM, Kim JW, Chung HT, Kim DG, Jung HW, Paek SH (2016) Fractionated stereotactic gamma knife radiosurgery for large brain metastases: a retrospective, single center study. PLoS ONE 11:e0163304.  https://doi.org/10.1371/journal.pone.0163304 CrossRefGoogle Scholar
  11. 11.
    Jeong WJ, Park JH, Lee EJ, Kim JH, Kim CJ, Cho YH (2015) Efficacy and safety of fractionated stereotactic radiosurgery for large brain metastases. J Korean Neurosurg Soc 58:217–224.  https://doi.org/10.3340/jkns.2015.58.3.217 CrossRefGoogle Scholar
  12. 12.
    Navarria P, Pessina F, Cozzi L, Ascolese AM, De Rose F, Fogliata A, Franzese C, Franceschini D, Tozzi A, D'Agostino G, Comito T, Iftode C, Maggi G, Reggiori G, Bello L, Scorsetti M (2016) Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. Radiat Oncol 11:76.  https://doi.org/10.1186/s13014-016-0653-3 CrossRefGoogle Scholar
  13. 13.
    Wegner RE, Leeman JE, Kabolizadeh P, Rwigema JC, Mintz AH, Burton SA, Heron DE (2015) Fractionated stereotactic radiosurgery for large brain metastases. Am J Clin Oncol 38:135–139.  https://doi.org/10.1097/COC.0b013e31828aadac CrossRefGoogle Scholar
  14. 14.
    Inoue HK, Sato H, Seto K, Torikai K, Suzuki Y, Saitoh J, Noda SE, Nakano T (2014) Five-fraction CyberKnife radiotherapy for large brain metastases in critical areas: impact on the surrounding brain volumes circumscribed with a single dose equivalent of 14 Gy (V14) to avoid radiation necrosis. J Radiat Res 55:334–342.  https://doi.org/10.1093/jrr/rrt127 CrossRefGoogle Scholar
  15. 15.
    Murai T, Ogino H, Manabe Y, Iwabuchi M, Okumura T, Matsushita Y, Tsuji Y, Suzuki H, Shibamoto Y (2014) Fractionated stereotactic radiotherapy using CyberKnife for the treatment of large brain metastases: a dose escalation study. Clin Oncol 26:151–158.  https://doi.org/10.1016/j.clon.2013.11.027 CrossRefGoogle Scholar
  16. 16.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972.  https://doi.org/10.1200/jco.2009.26.3541 CrossRefGoogle Scholar
  17. 17.
    Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger JC, Lunsford LD (2010) T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery 66:486–491.  https://doi.org/10.1227/01.Neu.0000360391.35749.A5 (discussion 491-482)CrossRefGoogle Scholar
  18. 18.
    Parvez K, Parvez A, Zadeh G (2014) The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci 15:11832–11846.  https://doi.org/10.3390/ijms150711832 CrossRefGoogle Scholar
  19. 19.
    Larsen VA, Simonsen HJ, Law I, Larsson HB, Hansen AE (2013) Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology 55:361–369.  https://doi.org/10.1007/s00234-012-1127-4 CrossRefGoogle Scholar
  20. 20.
    Tome WA (2009) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy: in regard to Parks et al. (Int J Radiat Oncol Biol Phys 2008;72:1620-1621). Int J Radiat Oncol Biol Phys 73:1286.  https://doi.org/10.1016/j.ijrobp.2008.12.001 CrossRefGoogle Scholar
  21. 21.
    Hall EJ, Brenner DJ (1993) The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 25:381–385CrossRefGoogle Scholar
  22. 22.
    Ling CC, Lo YC, Larson DA (1995) Radiobiophysical aspects of stereotaxic radiation treatment of central nervous system diseases. Semin Radiat Oncol 5:192–196.  https://doi.org/10.1054/srao00500192 CrossRefGoogle Scholar
  23. 23.
    Lehrer EJ, Peterson JL, Zaorsky NG, Brown PD, Sahgal A, Chiang VL, Chao ST, Sheehan JP, Trifiletti DM (2019) Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials. Int J Radiat Oncol Biol Phys 103:618–630.  https://doi.org/10.1016/j.ijrobp.2018.10.038 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guRepublic of Korea
  2. 2.Radiosurgery Center, Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guRepublic of Korea

Personalised recommendations